Latest News

Michael Ip, MD, presented a large-scale analysis of OCT biomarkers in diabetic macular edema (DME), drawing on data from the DRCR Retina Network's Protocol T trial.

Inflammasome Therapeutics announced positive phase 2 results achieved by kamuvudine-8 (K8), its investigational drug, for geographic atrophy (GA) and a good safety signal over the 6-month period of evaluation. The company also reported significantly slower GA progression and a visual acuity advantage.

The multicenter study is evaluating ZOC2017217, a lanosterol-derived investigational eye drop, ahead of a planned phase 3 trial.

Rising star in Ophthalmology, Nicholas Riina, MS, focuses on artificial intelligence and uses robotics training to enhance glaucoma diagnosis.

The randomized, double-masked, 3-arm trial did not achieve its primary endpoint of replicating the visual function improvements observed in a smaller phase 1/2a study.

Cynthia Toth, MD, of Duke University, discusses new BabySTEPS research showing that retinal nerve fiber layer and choroidal thickness on OCT correlate with 2-year neurodevelopmental outcomes in preterm infants and what it will take to bring bedside screening into routine NICU care.

Dry eye care pivots to root-cause diagnosis and personalized biologics/devices,

The long-term outcomes after primary scleral buckling procedures for rhegmatogenous retinal detachments showed high anatomic success, improved vision, and a good safety profile.

A new survey has discovered a gap between the value parents place on children's vision and the comprehensive eye care that teens and young adults receive.

Esen Akpek, MD, on dry eye's emotional and vision-related toll, its hidden autoimmune links, and when to move patients beyond artificial tears.

The non-exclusive license agreement pairs Alcon's PCIOL optical designs with RxSight's post-operative light-adjustable platform, with the aim of allowing surgeons to fine-tune visual outcomes after cataract surgery.

Antineoplastics were the most frequently implicated drug class in review

Cascade Prodrug and Uneedle are partnering to test suprachoroidal delivery of CPD100 using Uneedle's Bella-Vue microneedle system for the treatment of wet AMD.